Search Results - "Shapnik, Natalie"

Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma by Gleeson, Jack P, Nikolovski, Ines, Dinatale, Renzo, Zucker, Mark, Knezevic, Andrea, Patil, Sujata, Ged, Yasser, Kotecha, Ritesh R, Shapnik, Natalie, Murray, Samuel, Russo, Paul, Coleman, Jonathan, Lee, Chung Han, Stadler, Zsofia K, Hakimi, A Ari, Feldman, Darren R, Motzer, Robert J, Reznik, Ed, Voss, Martin H, Chen, Ying-Bei, Carlo, Maria I

“…Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare, aggressive form of RCC associated with hereditary leiomyomatosis and RCC syndrome…”
Get full text

Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report by Mahmood, Syed S., Chen, Carol L., Shapnik, Natalie, Krishnan, Udhay, Singh, Harsimran S., Makker, Vicky

“…Fulminant myocarditis has been reported in patients treated with immune checkpoint inhibitors. We present the first described case of acute immune-mediated…”
Get full text

Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations by Ged, Yasser, Gupta, Ruby, Duzgol, Cihan, Knezevic, Andrea, Shapnik, Natalie, Kotecha, Ritesh, Voss, Martin H, Feldman, Darren R, Akin, Oguz, Patil, Sujata, Motzer, Robert J, Rini, Brian I, Lee, Chung-Han

“…Several phase 3 studies reported positive results for combinations of Immune-Oncology (IO) and Vascular Endothelial Growth Factor (VEGF) targeted therapies in…”
Get full text

Next-generation sequencing based detection of germline and somatic alterations in a patient with four metachronous primary tumors by Martin, Madhuri, Sabari, Joshua K., Turashvili, Gulisa, Halpenny, Darragh F., Rizvi, Hira, Shapnik, Natalie, Makker, Vicky

“…Multiple primary tumors (MPTs) are defined as two or more separate synchronous or metachronous neoplasms occurring in different sites in the same individual…”
Get full text

Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates by Lee, Chung-Han, Voss, Martin H, Carlo, Maria Isabel, Chen, Ying-Bei, Zucker, Mark, Knezevic, Andrea, Lefkowitz, Robert A, Shapnik, Natalie, Dadoun, Chloe, Reznik, Ed, Shah, Neil J, Owens, Colette Ngozi, McHugh, Deaglan Joseph, Aggen, David Henry, Laccetti, Andrew Leonard, Kotecha, Ritesh, Feldman, Darren R, Motzer, Robert J

“…To assess the efficacy and safety of cabozantinib plus nivolumab in a phase II trial in patients with non-clear-cell renal cell carcinoma (RCC). Patients had…”
Get full text

Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma by Fitzgerald, Kelly N., Kotecha, Ritesh R, Knezevic, Andrea, Shapnik, Natalie, Aggen, David H, Carlo, Maria Isabel, Shah, Neil J., Voss, Martin H, Feldman, Darren R., Motzer, Robert J., Lee, Chung-Han

“…4545 Background: The role of somatic genomic mutations in predicting outcomes in clear cell renal cell carcinoma (ccRCC) is poorly defined. Both…”
Get full text

Impact of sarcomatoid features on treatment outcomes in metastatic clear cell renal cell carcinoma treated with first-line immunotherapy combinations by Fitzgerald, Kelly N., Duzgol, Cihan, Knezevic, Andrea, Shapnik, Natalie, Kotecha, Ritesh R, Aggen, David H, Carlo, Maria Isabel, Shah, Neil J., Voss, Martin H, Feldman, Darren R., Motzer, Robert J., Lee, Chung-Han

“…687 Background: The presence of sarcomatoid features in clear cell renal cell carcinoma (cRCC) has historically been associated with poor response to tyrosine…”
Get full text

Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations by Fitzgerald, Kelly N., Duzgol, Cihan, Knezevic, Andrea, Shapnik, Natalie, Kotecha, Ritesh, Aggen, David H., Carlo, Maria I., Shah, Neil J., Voss, Martin H., Feldman, Darren R., Motzer, Robert J., Lee, Chung-Han

“…In patients with metastatic clear cell renal cell carcinoma starting first-line treatment, there is no significant difference in progression-free survival…”
Get full text

Long-term outcomes of adrenal insufficiency (AI) due to anti–PD(L)-1 immune checkpoint inhibitors (ICI) among patients with cancer by Nguyen, Ben, Shah, Neil J., Knezevic, Andrea, Newman, Samantha, Fitzgerald, Kelly N., Kotecha, Ritesh, Lee, Chung-Han, Carlo, Maria Isabel, Aggen, David Henry, Feldman, Darren R., Shapnik, Natalie, Motzer, Robert J., Voss, Martin H, Girotra, Monica

“…12092 Background: Endocrine immune-related adverse events (irAEs) to anti-PD-(L)1 ICI, including hypophysitis, autoimmune insulin-dependent diabetes mellites…”
Get full text

Progression-free survival after second line of therapy (PFS-2) for metastatic clear cell renal cell carcinoma (ccRCC) in patients treated with first-line immunotherapy combinations by Fitzgerald, Kelly N., Duzgol, Cihan, Knezevic, Andrea, Shapnik, Natalie, Kotecha, Ritesh, Aggen, David Henry, Carlo, Maria Isabel, Shah, Neil J., Voss, Martin H, Feldman, Darren R., Motzer, Robert J., Lee, Chung-Han

“…4536 Background: Front-line therapy with immunotherapy combinations is standard of care for metastatic ccRCC, with ipilimumab/nivolumab (IO/IO) and several…”
Get full text

A phase II study of talazoparib and avelumab in VHL deficient clear cell renal cell carcinoma by Kotecha, Ritesh, Lee, Chung-Han, McHugh, Deaglan Joseph, Dadoun, Chloe, Knezevic, Andrea, Carlo, Maria Isabel, Feld, Emily, Shapnik, Natalie, Shah, Neil J., Feldman, Darren R., Motzer, Robert J., Voss, Martin H

“…Abstract only 347 Background: VHL inactivation may lead to impairments in the DNA damage response pathway and increased replication stress, which consequently…”
Get full text

Response to systemic therapy in patients with metastatic fumarate hydratase (FH) deficient renal cell carcinoma (RCC) by Gleeson, Jack Patrick, Nikolovski, Ines, Kotecha, Ritesh, Ged, Yasser, Shapnik, Natalie, Knezevic, Andrea, Feldman, Darren R., Lee, Chung-Han, Voss, Martin H, Chen, Ying-Bei, Motzer, Robert J., Carlo, Maria Isabel

“…Abstract only 686 Background: FH-deficient RCC (FHRCC) is characterized by unique pathologic features and lack of FH staining on immunohistochemistry (IHC)…”
Get full text

Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial by Lee, Chung-Han, Voss, Martin H, Carlo, Maria Isabel, Chen, Ying-Bei, Reznik, Eduard, Knezevic, Andrea, Lefkowitz, Robert A, Shapnik, Natalie, Tassone, Diana, Dadoun, Chloe, Shah, Neil J., Owens, Colette Ngozi, McHugh, Deaglan Joseph, Aggen, David Henry, Laccetti, Andrew Leonard, Kotecha, Ritesh, Feldman, Darren R., Motzer, Robert J.

“…Abstract only 4509 Background: Cabozantinib plus nivolumab (CaboNivo) improved objective response rate (ORR), progression-free survival (PFS), and overall…”
Get full text

Comprehensive Molecular Characterization and Response to Therapy in FH-Deficient Renal Cell Carcinoma by Gleeson, Jack P., Nikolovski, Ines, Dinatale, Renzo, Zucker, Mark, Knezevic, Andrea, Patil, Sujata, Ged, Yasser, Kotecha, Ritesh R, Shapnik, Natalie, Murray, Samuel, Russo, Paul, Coleman, Jonathan, Lee, Chung Han, Stadler, Zsofia K, Hakimi, A. Ari, Feldman, Darren R, Motzer, Robert J, Reznik, Ed, Voss, Martin H, Chen, Ying-Bei, Carlo, Maria I

Get full text

Systemic therapy for advanced clear cell renal cell carcinoma (ccRCC) after progression on immune-oncology plus VEGF targeted therapy combinations (IO-VEGF) by Ged, Yasser, Gupta, Ruby, Duzgol, Cihan, Shapnik, Natalie, Redzematovic, Almedina, Kotecha, Ritesh, Voss, Martin Henner, Feldman, Darren R., Akin, Oguz, Patil, Sujata, Motzer, Robert J., Rini, Brian I., Lee, Chung-Han

“…Abstract only 4576 Background: IO-VEGF combinations are the backbone for current and future therapeutic developments in RCC with several IO-VEGF regimens…”
Get full text

Genomic biomarkers of response to lenvatinib/pembrolizumab (Len/Pembro) in patients with advanced renal cell carcinoma by Lee, Chung-Han, DiNatale, Renzo G., Chowell, Diego, Krishna, Chriag, Makarov, Vladimir, Shapnik, Natalie, Murray, Samuel J., Carlo, Maria Isabel, Voss, Martin H, Feldman, Darren R., Hakimi, A. Ari, Adachi, Yusuke, Minoshima, Yukinori, Matsui, Junji, Funahashi, Yasuhiro, Perini, Rodolfo F., Nomoto, Kenichi, Motzer, Robert J., Chan, Timothy An-thy

“…Abstract only 733 Background: A phase 1b/2 clinical trial indicated that len/pembro shows promise in the treatment of renal cell carcinoma (RCC) in both…”
Get full text

Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma by Kotecha, Ritesh R, Gedvilaite, Erika, Ptashkin, Ryan, Knezevic, Andrea, Murray, Samuel, Johnson, Ian, Shapnik, Natalie, Feldman, Darren R, Carlo, Maria I, Shah, Neil J, Dunigan, Marisa, Huberman, Kety, Benayed, Ryma, Zehir, Ahmet, Berger, Michael F, Ladanyi, Marc, Tsui, Dana W Y, Motzer, Robert J, Lee, Chung-Han, Voss, Martin H

“…The clinical utility of cell-free DNA (cfDNA) as a biomarker for advanced clear cell renal cell carcinoma (ccRCC) remains unclear. We evaluated the validity of…”
Get more information

Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report by Mahmood, Syed S, Chen, Carol L, Shapnik, Natalie, Krishnan, Udhay, Singh, Harsimran S, Makker, Vicky

“…BACKGROUNDFulminant myocarditis has been reported in patients treated with immune checkpoint inhibitors. We present the first described case of acute…”
Get full text